Trial · NCT00570401

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

NCT00570401, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2016-01-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib. Trials, record NCT00570401. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00570401

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
NCT number: NCT00570401
Status: Completed
Phases: Phase 2
Enrollment: 22 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Lung Cancer
Interventions: dasatinib
First posted: 2007-12-10
Last updated: 2016-01-22
Results first posted: 2016-01-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Determine the Overall Objective Response	2 years	To determine the overall response rate in patients with acquired erlotinib hydrochloride- or gefitinibresistant advanced adenocarcinoma of the lung treated with dasatinib using the RECIST criteria. Response and progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.22 Changes in only the largest diameter (uni-dimensional measurement) of the tumor lesions are used in the RECIST.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Determine the Overall Objective Response	2 years		participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Determine the Overall Objective Response	Dasatinib	Stable Disease (SD)	6		participants
Determine the Overall Objective Response	Dasatinib	Progression of Disease (POD)	13		participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dasatinib	21
Overall Study	COMPLETED	Dasatinib	19
Overall Study	NOT COMPLETED	Dasatinib	2

Source ClinicalTrials.gov

Adverse events26

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Albumin, low (hypoalbuminemia)	Metabolism and nutrition disorders	Dasatinib	5	21	5
other	Alkaline phosphatase	Metabolism and nutrition disorders	Dasatinib	2	21	2
other	ALT, SGPT	Blood and lymphatic system disorders	Dasatinib	2	21	2
other	Bilirubin (hyperbilirubinemia)	Metabolism and nutrition disorders	Dasatinib	2	21	2
other	Constipation	Gastrointestinal disorders	Dasatinib	3	21	3
other	Cough	Respiratory, thoracic and mediastinal disorders	Dasatinib	3	21	3
other	Dyspnea (shortness of breath)	Respiratory, thoracic and mediastinal disorders	Dasatinib	8	21	8
other	Fatigue (asthenia, lethargy, malaise)	General disorders	Dasatinib	9	21	9
other	Glucose, high (hyperglycemia)	Metabolism and nutrition disorders	Dasatinib	4	21	4
other	Hemoglobin	Blood and lymphatic system disorders	Dasatinib	4	21	4

1 to 10 of 26Source ClinicalTrials.gov

See all 26 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dasatinib
Total, other adverse events	Dasatinib	15	21
Total, serious adverse events	Dasatinib	12	21

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
21623279	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA008748	Cancer Center Support Grant	Rudin, Charles M.	SLOAN-KETTERING INST CAN RESEARCH	NATIONAL CANCER INSTITUTE	1985 to 2026

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00570401

GET https://conductscience.org/api/trials/v1/NCT00570401/events?page=2

API reference For AI assistants